M3 : Notice Concerning Differences between Actual Non-Consolidated Results for the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year Ended March 31, 2023
April 26, 2024 at 10:36 am EDT
Share
FOR IMMEDIATE RELEASE: 2024/4/26
Listed Name:
M3, Inc.
(TSE Prime Market, Ticker Code: 2413)
Headquarters:
(https://corporate.m3.com/en)
1-11-44 Akasaka, Minato-ku, Tokyo
Representative:
Itaru Tanimura, Representative Director
Contact:
Hirofumi Oba, Corporate Officer
Notice Concerning Differences between Actual Non-Consolidated Results
for the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year Ended March 31, 2023
This notice serves to provide information regarding the difference between actual non-consolidated results for the fiscal year ended March 31, 2024 and the results for the previous fiscal year ended March 31, 2023.
1. Differences between actual non-consolidated results for the fiscal year ended March 31, 2024 and the fiscal year ended March 31, 2023 (J-GAAP)
Net sales
Operating profit
Ordinary profit
Profit
Actual results for the
Millions of Yen
Millions of Yen
Millions of Yen
Millions of Yen
fiscal year ended
54,530
26,503
27,992
19,783
March 31, 2023 (A)
Actual results for the
fiscal year ended
51,520
23,596
84,032
75,943
March 31, 2024 (B)
Difference (B - A)
-3,010
-2,907
+56,039
+56,160
Difference (%)
-5.5
-11.0
+200.2
+283.9
2. Reason of differences
Net sales and operating profit for non-consolidated results for the fiscal year ended March 31, 2024 were lower than the previous fiscal year, mainly due to a year-on-year decline in sales of pharmaceutical marketing support business, affected by marketing budget constraints by pharmaceutical companies.
On the other hand, ordinary profit and profit were significantly higher than the previous fiscal year, due to the receipt of dividends from consolidated subsidiaries, as disclosed in the "Announcement of Receipt of Dividends from Consolidated Subsidiaries" released on March 22, 2024. As stated in the above announcement, there is no impact on the Company's consolidated financial results for the fiscal year ended March 31, 2024, since these are dividends from consolidated subsidiaries.
Attachments
Original Link
Original Document
Permalink
Disclaimer
M3 Inc. published this content on
26 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
26 April 2024 14:36:21 UTC.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.
M3 : Notice Concerning Differences between Actual Non-Consolidated Results for the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year Ended March 31, 2023